Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
baca selengkapnya
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
556 hari yang lalu
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
872 hari yang lalu
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
984 hari yang lalu
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
1341 hari yang lalu
U.S. Dollar Advances Amid Middle East Tensions, Tech Sector Slide
The U.S. Dollar value moved higher on Friday after the U.S. and Iran adopted a tougher stance against any agreement and trounced expectations for a deal to end their conflict and reopen the Strait of Hormuz. In addition, the slide in the IT stocks due to Nvidia crisis weighed on the equity markets.
RTTNews
|
17 jam 15 menit yang lalu
Canadian Stocks Turning In Mixed Performance As Investors React To Earnings
Canadian stocks are turning in a mixed performance on Friday with investors reacting to corporate earnings updates, and also weighing the potential impact of the resignation of Nvidia co-founder and CEO Jensen Huang on the tech sector.
RTTNews
|
19 jam 54 menit yang lalu
Swiss Market Ends On Weak Note
The Switzerland stock market ended modestly lower on Friday after languishing in negative territory throughout the trading session, as traders seemed reluctant to build up fresh positions amid a lack of positive news.
RTTNews
|
20 jam 40 menit yang lalu
European Stocks End On Mixed Note After Cautious Session
European stocks turned in a mixed performance on Friday as investors made cautious moves amid uncertainty over the outlook for the AI trade and possibility of a rate hike by the Federal Reserve in December. Optimism about corporate earnings aided sentiment a bit.
RTTNews
|
21 jam 12 menit yang lalu
